1. Home
  2. ACR vs LCTX Comparison

ACR vs LCTX Comparison

Compare ACR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACR
  • LCTX
  • Stock Information
  • Founded
  • ACR 2005
  • LCTX 1990
  • Country
  • ACR United States
  • LCTX United States
  • Employees
  • ACR N/A
  • LCTX N/A
  • Industry
  • ACR Real Estate Investment Trusts
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACR Real Estate
  • LCTX Health Care
  • Exchange
  • ACR Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • ACR 136.9M
  • LCTX 110.2M
  • IPO Year
  • ACR N/A
  • LCTX N/A
  • Fundamental
  • Price
  • ACR $17.01
  • LCTX $0.51
  • Analyst Decision
  • ACR Buy
  • LCTX Strong Buy
  • Analyst Count
  • ACR 2
  • LCTX 4
  • Target Price
  • ACR $17.50
  • LCTX $5.25
  • AVG Volume (30 Days)
  • ACR 13.3K
  • LCTX 4.2M
  • Earning Date
  • ACR 10-30-2024
  • LCTX 11-14-2024
  • Dividend Yield
  • ACR N/A
  • LCTX N/A
  • EPS Growth
  • ACR N/A
  • LCTX N/A
  • EPS
  • ACR 0.83
  • LCTX N/A
  • Revenue
  • ACR $77,437,000.00
  • LCTX $8,719,000.00
  • Revenue This Year
  • ACR N/A
  • LCTX N/A
  • Revenue Next Year
  • ACR N/A
  • LCTX $123.52
  • P/E Ratio
  • ACR $20.77
  • LCTX N/A
  • Revenue Growth
  • ACR 8.77
  • LCTX N/A
  • 52 Week Low
  • ACR $9.41
  • LCTX $0.48
  • 52 Week High
  • ACR $17.77
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • ACR 52.63
  • LCTX 35.09
  • Support Level
  • ACR $17.09
  • LCTX $0.50
  • Resistance Level
  • ACR $17.53
  • LCTX $0.61
  • Average True Range (ATR)
  • ACR 0.24
  • LCTX 0.05
  • MACD
  • ACR -0.10
  • LCTX 0.00
  • Stochastic Oscillator
  • ACR 0.64
  • LCTX 24.24

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: